Buccolam: prescribe by brand name to reduce medication errors

New guidance on the prescribing of buccal midazolam products has been issued by the Welsh medicines assessment body.

Buccolam is available in colour-coded pre-filled oral syringes, with age-specific doses, to reduce the risk of medication error
Buccolam is available in colour-coded pre-filled oral syringes, with age-specific doses, to reduce the risk of medication error

The All Wales Medicines Strategy Group (AWMSG) has highlighted the importance of prescribing Buccolam (buccal midazolam) by brand name to reduce the risk of medication errors.

Buccal midazolam is approved for the treatment of prolonged, acute, convulsive seizures in children aged between 3 months and 18 years. It has anticonvulsant, sedative and muscle-relaxant effects.

Treatment of infants 3–6 months of age should take place in the hospital setting, where monitoring and resuscitation equipment is available.

View Buccolam drug record

Further information: ViroPharma Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases